A MYD88 L265P mutation test looks for a specific acquired change in the MYD88 gene that is strongly associated with lymphoplasmacytic lymphoma (LPL) and Waldenström macroglobulinemia (WM). The mutation activates signaling pathways that promote survival of the abnormal B-cell clone. It is detectable in more than 90% of many WM series and is therefore highly useful when the diagnosis is uncertain, especially in a patient with an IgM monoclonal protein and bone marrow lymphoplasmacytic infiltration.
A positive MYD88 L265P result supports LPL/WM but does not prove it by itself. The mutation can also occur in IgM monoclonal gammopathy of undetermined significance (MGUS) and in selected other B-cell lymphomas, including some diffuse large B-cell lymphomas. A negative result does not exclude WM because a minority of cases are MYD88 wild-type, and assay sensitivity can vary. The best interpretation combines the molecular result with bone marrow morphology, flow cytometry or immunohistochemistry, serum IgM studies, and clinical findings.
- What it measures: The test detects the MYD88 p.L265P gain-of-function mutation in tumor DNA, usually from bone marrow or blood containing the abnormal clone.
- What a positive result means: It strongly supports LPL/WM in the right clinical setting but is not specific enough to replace marrow and monoclonal-protein evaluation.
- What a negative result means: MYD88 wild-type disease remains possible; a low tumor fraction or less sensitive method can also produce a false-negative result.
- Why it matters in WM: MYD88 status helps with diagnosis and may provide treatment-relevant context, especially alongside CXCR4 mutation status.
- Preparation: No fasting is generally required. Bone marrow is often the preferred diagnostic specimen because the disease primarily involves marrow.
Table of Contents
- What MYD88 L265P is
- When the test is ordered
- What a positive result means
- What a negative result means
- MYD88 in Waldenström and LPL diagnosis
- Testing methods and sensitivity
- Treatment context and next steps
What MYD88 L265P is
MYD88 encodes an adaptor protein used by Toll-like receptor and interleukin-1 receptor signaling. In normal immune cells, these pathways turn on in response to specific signals and help activate NF-κB and other survival programs.
The L265P mutation replaces leucine with proline at amino acid 265. This change promotes persistent MYD88 signaling and can activate downstream pathways including IRAK and Bruton tyrosine kinase signaling. In LPL/WM, that abnormal signaling helps the clonal lymphoplasmacytic cells survive.
The mutation is important because it is common in WM but less common in several conditions that can look similar. That makes it a useful supportive diagnostic marker.
It is not unique to WM. MYD88 L265P can be detected in some patients with IgM MGUS and in subsets of other mature B-cell neoplasms, particularly activated B-cell–type diffuse large B-cell lymphoma and lymphomas arising in certain immune-privileged sites. The diagnosis therefore cannot be made from MYD88 status alone.
A broader MYD88 mutation test may survey more than L265P depending on the assay. The current test is focused on the canonical L265P variant that has the strongest established association with LPL/WM.
When the test is ordered
MYD88 testing is most useful when clinicians are evaluating an IgM monoclonal gammopathy or a marrow infiltrate with small B cells and plasmacytic differentiation.
Common reasons to order it include:
- suspected Waldenström macroglobulinemia;
- suspected lymphoplasmacytic lymphoma;
- differentiating LPL/WM from marginal zone lymphoma or another indolent B-cell lymphoma;
- evaluating an IgM monoclonal gammopathy with marrow involvement;
- clarifying a difficult marrow biopsy with plasmacytic differentiation; and
- obtaining molecular information before treatment when current practice recommends a broader WM molecular workup.
The presence of an IgM M protein does not by itself establish WM. IgM MGUS, marginal zone lymphoma, chronic lymphocytic leukemia, plasma-cell disorders, and other conditions can produce monoclonal IgM.
A serum immunofixation test identifies the monoclonal immunoglobulin type, while the marrow determines whether there is a lymphoplasmacytic lymphoma infiltrate. MYD88 testing adds molecular support to that picture.
What a positive result means
A positive MYD88 L265P result strongly supports LPL/WM when the patient also has the appropriate marrow morphology and IgM monoclonal protein. It can be particularly helpful when the biopsy differential includes another small B-cell lymphoma with plasmacytic differentiation.
The mutation is found in the great majority of WM cases. It is also common in the non-plasma-cell type of IgM MGUS, so a positive result cannot distinguish asymptomatic precursor disease from symptomatic WM by itself.
A positive result should be read alongside:
- serum IgM concentration and immunofixation;
- bone marrow percentage and pattern of lymphoplasmacytic infiltration;
- flow cytometry or immunohistochemistry;
- blood counts;
- symptoms attributable to tumor infiltration or IgM; and
- CXCR4 and other molecular findings when tested.
Does MYD88 positivity mean treatment is needed?
No. WM treatment is based on symptoms and clinically important disease effects, not mutation positivity alone. Many people with WM can be observed without treatment if they are asymptomatic.
Treatment may become necessary for problems such as symptomatic anemia, significant thrombocytopenia, bulky lymphadenopathy or splenomegaly, hyperviscosity, symptomatic neuropathy, cryoglobulinemia, cold-agglutinin complications, or other IgM-related disease manifestations.
A mutation can be present for years in an indolent clone. Its diagnostic value should not be confused with an indication to start therapy.
What a negative result means
A negative MYD88 L265P result means the assay did not detect the canonical mutation above its validated threshold. This has two possible broad explanations: the disease is truly MYD88 wild-type, or the assay lacked enough sensitivity or tumor DNA to detect the mutation.
A minority of bona fide WM cases are MYD88 wild-type. These cases deserve careful diagnostic review because the differential diagnosis broadens. The pathologist may reconsider marginal zone lymphoma, IgM plasma-cell myeloma, chronic lymphocytic leukemia, or another B-cell neoplasm depending on morphology and phenotype.
Why false-negative results can occur
False negatives can result from:
- low marrow tumor burden;
- testing unfractionated blood when few clonal cells circulate;
- DNA degradation;
- an assay with limited analytical sensitivity;
- a small clone below the detection limit; or
- a non-L265P MYD88 variant not covered by the specific test.
Bone marrow is often more informative than peripheral blood for diagnostic testing because WM primarily involves marrow. Enriching CD19-positive B cells or using highly sensitive allele-specific PCR or digital PCR can improve detection in low-burden samples.
A negative result should therefore be interpreted as “not detected by this assay,” not “WM ruled out.”
MYD88 in Waldenström and LPL diagnosis
Waldenström macroglobulinemia is a clinicopathologic form of LPL characterized by an IgM monoclonal protein. The diagnosis requires evidence of a clonal lymphoplasmacytic marrow process in the appropriate clinical context.
The marrow may contain small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Flow cytometry often shows a clonal B-cell population expressing B-cell markers with variable CD25 and other antigens, while the plasma-cell component can show light-chain restriction.
MYD88 helps because several look-alike disorders have different molecular tendencies.
| Condition | Typical MYD88 L265P relationship | Why other tests still matter |
|---|---|---|
| LPL/Waldenström macroglobulinemia | Present in most cases | Requires marrow and IgM clinicopathologic correlation |
| IgM MGUS | Can be present | Does not establish symptomatic WM |
| Marginal zone lymphoma | Usually absent but not impossible | Morphology, site, phenotype, and genetics separate entities |
| IgM plasma-cell myeloma | Typically absent | Plasma-cell phenotype, cytogenetics, bone disease, and marrow pattern matter |
| DLBCL | Present in selected molecular/site-defined subsets | Large-cell morphology and lymphoma classification dominate interpretation |
This molecular distinction is especially useful when the marrow has plasmacytic differentiation but lacks a classic appearance.
A lymphoma flow cytometry panel can define the clonal B-cell phenotype. MYD88 adds a separate molecular layer that helps place the clone in the correct disease family.
Testing methods and sensitivity
Several laboratory methods can detect MYD88 L265P. They differ in breadth and sensitivity.
Allele-specific PCR
Allele-specific PCR is designed specifically for the L265P variant and can achieve high sensitivity. It is well suited to a known hotspot and is commonly recommended in WM-focused diagnostic workflows.
Digital PCR
Droplet digital PCR partitions the sample into many microscopic reactions and can detect very low variant levels. It can be useful when tumor burden is low and can provide a quantitative estimate of mutant allele frequency.
Next-generation sequencing
NGS surveys many genes at once, which is useful when the clinician wants a broader lymphoma panel. However, routine NGS assays may have lower sensitivity for MYD88 L265P than dedicated allele-specific or digital PCR, particularly in low-burden samples. A technically “negative” NGS result may therefore need confirmation with a more sensitive method when the clinical suspicion for WM is strong.
Variant allele frequency
Some reports provide variant allele frequency (VAF). VAF is the fraction of sequencing reads carrying the mutation. It is influenced by tumor fraction, normal-cell contamination, copy number, and assay design. It should not be interpreted as a direct percentage of cancer cells.
A low VAF can still be genuine and clinically useful. The key questions are whether the variant is confidently detected and whether the specimen contains enough disease for the assay to be reliable.
Treatment context and next steps
MYD88 status can provide treatment-relevant context because MYD88 signaling interacts with Bruton tyrosine kinase pathways targeted by BTK inhibitors. However, treatment selection is more nuanced than “MYD88 positive equals BTK inhibitor.” Age, symptoms, comorbidities, disease burden, prior therapy, CXCR4 status, and drug-specific risks all matter.
A CXCR4 mutation test is often paired with MYD88 in a modern WM molecular workup because CXCR4 mutations can affect disease biology and response kinetics to some BTK inhibitors.
Consensus recommendations also support assessing other abnormalities in selected patients, including TP53 and chromosome 6q/17p findings, especially when treatment is being planned.
After a MYD88 result, useful questions include:
- Does the marrow morphology actually support LPL?
- Is the monoclonal protein IgM, and how high is it?
- Is this IgM MGUS, asymptomatic WM, or symptomatic WM?
- Was the test performed on marrow, blood, or enriched B cells?
- What was the assay sensitivity?
- If negative, should a more sensitive method be used?
- Is CXCR4 testing indicated?
- Are current symptoms caused by the lymphoma, by IgM, or by another condition?
Patients with very high IgM can develop hyperviscosity, which may cause blurred vision, headache, dizziness, nose or gum bleeding, or neurologic symptoms. Suspected symptomatic hyperviscosity requires urgent medical assessment because plasma exchange may be needed before or alongside systemic therapy.
The central point is straightforward: MYD88 L265P is a powerful supportive marker for LPL/WM, but the diagnosis and need for treatment come from the full clinical-pathologic picture.
Why bone marrow is often more informative than peripheral blood
Waldenström macroglobulinemia is defined by an IgM monoclonal protein together with bone marrow involvement by lymphoplasmacytic lymphoma. The neoplastic cells may circulate only sparsely, so peripheral blood can contain much less mutant DNA than marrow. A negative blood MYD88 result therefore carries less exclusionary power when the clinical suspicion is high.
Assay sensitivity also matters. Allele-specific PCR and digital PCR can detect low levels of MYD88 L265P that some broader NGS panels may miss, especially when the tumor fraction is small. Laboratories should interpret a negative result in light of specimen type, tumor content, and the method’s limit of detection. If the marrow morphology and IgM pattern remain strongly suggestive, a negative low-sensitivity assay may justify repeat or more sensitive testing rather than immediate rejection of the diagnosis.
MYD88 helps with the differential diagnosis, but it is not unique to WM
MYD88 L265P is present in the great majority of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma cases, which makes it a powerful supportive marker. It can also occur in other B-cell neoplasms, including some marginal zone lymphomas and certain diffuse large B-cell lymphomas. Conversely, a minority of otherwise convincing lymphoplasmacytic lymphomas are MYD88 wild type.
The result is therefore most useful when it answers a focused question: does the molecular finding support the marrow morphology and IgM paraprotein pattern? It should not be used as a stand-alone label for Waldenström macroglobulinemia.
How MYD88 and CXCR4 can influence treatment discussions
MYD88 and CXCR4 are biologically linked to signaling pathways that can affect response patterns to Bruton tyrosine kinase inhibitors. In clinical practice, MYD88 mutation status may be considered when selecting among therapies, particularly if a BTK inhibitor is being discussed. CXCR4 mutation can add further context because it may influence depth or speed of response with some agents.
These molecular associations are not absolute treatment rules. Symptoms requiring therapy, prior treatments, neuropathy, cardiovascular risk, bleeding risk, other illnesses, drug interactions, and patient preference also matter. The most useful question is whether the mutation result changes the choice among otherwise reasonable treatments for that specific patient.
MYD88 is not the main test for measuring disease burden
MYD88 testing is primarily a diagnostic and biologic marker. Routine response assessment in Waldenström macroglobulinemia relies more on the patient’s symptoms, examination, blood counts, serum IgM, and other disease features than on repeatedly measuring MYD88 allele burden. IgM trends themselves also need context because the protein level can change at a different pace from marrow disease, and certain treatments can produce an early IgM flare.
A rising IgM value is therefore not interpreted from one measurement alone. Clinicians consider whether the increase is confirmed, whether symptoms or cytopenias are worsening, and whether there are complications such as hyperviscosity, neuropathy, cryoglobulinemia, or organ involvement. Molecular status helps define the disease; it does not replace clinical response criteria.
What MYD88 wild type can mean
A truly MYD88-wild-type lymphoplasmacytic process deserves careful review because the classic L265P mutation is so common in Waldenström macroglobulinemia. The possibilities include a genuine MYD88-wild-type LPL/WM, a false-negative result caused by low tumor content or assay sensitivity, or a different small B-cell lymphoma with plasmacytic differentiation.
In that setting, the marrow morphology, immunophenotype, IgM paraprotein, chromosome findings, and additional molecular tests become especially important. The goal is not to force every IgM-producing lymphoma into the Waldenström category, but to identify the entity that best fits all available evidence.
The urgency of evaluation depends on symptoms, not mutation status alone. Hyperviscosity can cause visual changes, headache, confusion, mucosal bleeding, or shortness of breath and may require urgent treatment when IgM is markedly elevated and symptoms are compatible. A positive MYD88 result does not predict who is having an emergency; the patient’s neurologic, bleeding, cardiopulmonary, and eye symptoms take priority over the molecular report.
When a result is positive, ask whether the exact variant is MYD88 L265P, which assay detected it, and whether CXCR4 testing is available or clinically useful. When it is negative, ask whether marrow rather than blood was tested and whether the method was sensitive enough for the estimated tumor burden.
The result is most reliable when molecular, protein, marrow, and clinical findings all point in the same direction.
References
- Report of Consensus Panel 3 from the 11th International workshop on Waldenström’s Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström’s Macroglobulinemia 2023 (Guideline)
- Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom’s macroglobulinemia on diagnostic and response criteria 2023 (Guideline)
- Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia 2023 (Guideline)
- Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management 2025 (Review)
- Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia, a decade after the discovery of MYD88L265P 2024 (Review)
- Diagnostic next-generation sequencing to detect MYD88 L265P in Lymphoplasmacytic lymphoma compared to ddPCR 2025
Disclaimer
This article is for general educational information and is not a substitute for diagnosis or treatment by a hematologist or hematopathologist. MYD88 status must be interpreted with marrow findings, monoclonal IgM studies, clinical symptoms, and other molecular tests. Seek urgent care for symptoms suggesting hyperviscosity, including new vision changes, significant bleeding, confusion, severe headache, or neurologic deficits.
